母亲接种Tdap疫苗与婴儿发病风险
该回顾性队列研究纳入美国七个VSD医疗系统的197,564例单胎活产,评估孕期接种Tdap与绒毛膜羊膜炎及婴儿特定疾病的关系。孕期接种Tdap者绒毛膜羊膜炎发生率为6.4%,未接种者为5.2%(ARR 1.23,95%CI 1.17-1.28);婴儿短暂性呼吸急促、新生儿败血症、新生儿肺炎、呼吸窘迫综合征及新生儿惊厥的风险均无显著升高。
要点
- 孕期接种Tdap者绒毛膜羊膜炎发生率为6.4%,未接种者为5.2%(ARR 1.23,95%CI 1.17-1.28)。
- 婴儿短暂性呼吸急促ARR 1.04(95%CI 0.98-1.11),风险无显著升高。
- 新生儿败血症、肺炎、呼吸窘迫综合征及惊厥的风险均无显著升高。
核心结论
- 尽管观察到母亲接种Tdap疫苗与母亲绒毛膜羊膜炎之间存在关联,但未发现与母亲绒毛膜羊膜炎相关的临床显著婴儿结局风险增加。
研究设计与样本
- 回顾性队列研究,纳入2010年1月1日至2013年11月15日期间在美国七个VSD医疗系统内连续参保(从末次月经前6个月至产后6周)且孕期至少一次门诊就诊的单胎活产孕妇,共197,564例妊娠。
主要发现
- 孕期任何时间接种Tdap者绒毛膜羊膜炎发生率为6.4%,未接种者为5.2%(ARR 1.23,95%CI 1.17-1.28)。
- 与未接种孕妇相比,接种Tdap孕妇所生婴儿的短暂性呼吸急促ARR 1.04(95%CI 0.98-1.11),风险无显著升高。
- 新生儿败血症ARR 1.06(95%CI 0.91-1.23),风险无显著升高。
- 新生儿肺炎ARR 0.94(95%CI 0.72-1.22),风险无显著升高。
- 呼吸窘迫综合征ARR 0.91(95%CI 0.66-1.26),风险无显著升高。
关键数值与推荐
- Tdap暴露窗口包括推荐孕27-36周或孕期任何时间。
- 采用泊松分布和对数链接的广义线性模型估计倾向评分调整后的率比(ARR)及95%CI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: An increased risk of diagnosed chorioamnionitis in women vaccinated with Tdap during pregnancy was previously detected at two Vaccine Safety Datalink (VSD) sites. The clinical significance of this finding related to infant outcomes remains uncertain. METHODS: Retrospective cohort study of singleton live births born to women who were continuously insured from 6months prior to their last menstrual period through 6weeks postpartum, with ≥1 outpatient visit during pregnancy from January 1, 2010 to November 15, 2013 at seven integrated United States health care systems part of the VSD. We re-evaluated the association between maternal Tdap and chorioamnionitis and evaluated whether specific infant morbidities differ among infants born to mothers who did and did not receive Tdap during pregnancy. We focused on 2 Tdap exposure windows: the recommended 27-36weeks gestation or anytime during pregnancy. We identified inpatient diagnostic codes for transient tachypnea of the newborn (TTN), neonatal sepsis, neonatal pneumonia, respiratory distress syndrome (RDS), and newborn convulsions associated with an infant's first hospitalization. A generalized linear model with Poisson distribution and log-link was used to estimate propensity score adjusted rate ratios (ARR) with 95% confidence intervals (CI). RESULTS: The analyses included 197,564 pregnancies. Chorioamnionitis was recorded in 6.4% of women who received Tdap vaccination any time during pregnancy and 5.2% of women who did not (ARR [95% CI]: 1.23 [1.17, 1.28]). Compared with unvaccinated women, there were no significant increased risks (ARR [95% CI]) for TTN (1.04 [0.98, 1.11]), neonatal sepsis (1.06 [0.91, 1.23]), neonatal pneumonia (0.94 [0.72, 1.22]), RDS (0.91 [0.66, 1.26]), or newborn convulsions (1.16 [0.87, 1.53]) in infants born to Tdap-vaccinated women. CONCLUSIONS AND RELEVANCE: Despite an observed association between maternal Tdap vaccination and maternal chorioamnionitis, we did not find increased risk for clinically significant infant outcomes associated with maternal chorioamnionitis.
引用
- DeSilva M, Vazquez-Benitez G, Nordin JD, et al. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017. PMID: 28552511. doi:10.1016/j.vaccine.2017.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。